Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1495 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 January 2020 | Suspended. Topic has been suspended |
| 22 January 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 18 July 2019 - 15 August 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 June 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. Following on from information received from the company, please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid- November 2019. |
| 11 January 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer. Following on from information received from the company, please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2019. |
| 02 October 2018 - 30 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 October 2018 | On receiving updated regulatory timing information from the company that markets the technology, NICE has agreed that scoping the topic at this time would not be appropriate. Consequently the consultation on the draft scope will not continue. The consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk |
| 24 April 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual